IO Frontiers World 2019


Linda Powers

Linda Powers

Chief Executive Officer, Northwest Biotherapeutics
Ms. Powers has served as the Chairman of NW Bio since 2007, and as CEO since 2011. Ms. Powers previously served as a Managing Director of Toucan Capital Fund II, an investment fund focused on regenerative medicine and immune therapies, from 2001 to 2010. In addition, she has over 15 years’ experience in corporate finance and restructurings, mergers and acquisitions, joint ventures and intellectual property licensing. Ms. Powers has served for many years on a number of boards and commissions, including M2GEN (an affiliate of Moffitt Cancer Center), the Chinese Biopharmaceutical Association, the Rosalind Franklin Society, the Maryland Stem Cell Research Commission, a Steering Committee of the National Academy of Sciences evaluating government research funding, and three Governors’ commissions focused on building biotech and other industries. Ms. Powers taught for more than six years at the National Institutes of Health, on medical product development and commercialization, and at Georgetown Law School as an adjunct professor. Ms. Powers serves on the boards of a number of private biotechnology companies. Ms. Powers holds a B.A. from Princeton University, magna cum laude, and a J.D. from Harvard Law School, magna cum laude.
  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy